Market Cap (In USD)
201.56 Thousand
Revenue (In USD)
2.23 Million
Net Income (In USD)
-42.19 Million
Avg. Volume
22.94 Thousand
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 0.0384-0.06
- PE
- 0.07
- EPS
- 0.292
- Beta Value
- 0.641
- ISIN
- US78397T1117
- CUSIP
- 78397T111
- CIK
- 1833214
- Shares
- 9288870.0
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Samuel J. Reich
- Employee Count
- -
- Website
- http://www.sabbiotherapeutics.com
- Ipo Date
- 2021-10-25
- Details
- SAB Biotherapeutics, Inc., a biopharmaceutical company, develops immunotherapies against infectious diseases, autoimmune diseases, and oncology. It offers SAB-142 anti-thymocyte globulin for Type 1 diabetes; SAB-176 for seasonal influenza; and SAB-301 for Middle East Respiratory Syndrome Coronavirus (MERS-COV). SAB Biotherapeutics, Inc. was incorporated in 2014 and is based in Sioux Falls, South Dakota with an additional office in Cambridge, Massachusetts.
More Stocks
-
SANCOSanco Industries Limited
SANCO
-
9519RENOVA, Inc.
9519
-
U1DAClockchain AG
U1DA
-
SHREYANINDShreyans Industries Limited
SHREYANIND
-
TGLOtheglobe.com, inc.
TGLO
-
HCH
-
002424
-
RAJRATANRajratan Global Wire Limited
RAJRATAN